Filtered By:
Therapy: Immunotherapy

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 258 results found since Jan 2013.

Evaluation of a DoE based approach for comprehensive modelling of the effect of lipid nanoparticle composition on nucleic acid delivery
Biomaterials. 2023 May 15;299:122158. doi: 10.1016/j.biomaterials.2023.122158. Online ahead of print.ABSTRACTTherapeutic nucleic acids (TNAs) comprise an alternative to conventional drugs for cancer therapy. Recently, stable nucleic acid lipid particles (SNALPs) have been explored to deliver TNA efficiently and safely both in vitro and in vivo. Small interfering RNA (siRNA) and messenger RNA (mRNA) based drugs have been suggested for a wide range of pathologies, and their respective lipid nanoparticle (LNP) formulations have been optimised using a Design of Experiments (DoE) approach. However, it is uncertain as to whether...
Source: Biomaterials - May 27, 2023 Category: Materials Science Authors: Yue Qin Adam A Walters Nadia Rouatbi Julie Tzu-Wen Wang Hend Mohamed Abdel-Bar Khuloud T Al-Jamal Source Type: research

Core-shell tecto dendrimer-mediated cooperative chemoimmunotherapy of breast cancer
J Control Release. 2023 May 16:S0168-3659(23)00334-6. doi: 10.1016/j.jconrel.2023.05.021. Online ahead of print.ABSTRACTDevelopment of effective nanomedicines to deal with tumor immunogenicity and immunosuppression is vital to improve the immunotherapy efficacy. Herein, we developed a programmed strategy not only to activate the tumoral immune microenvironment through immunogenic cell death (ICD) effect but also to promote the maturation of dendritic cells (DCs) in lymph nodes through two modules of core-shell tecto dendrimer (CSTD)-based nanomedicines. The CSTDs with amplified tumor enhanced permeability and retention eff...
Source: Cancer Control - May 18, 2023 Category: Cancer & Oncology Authors: Cong Song Mengsi Zhan Zhijun Ouyang Yuge Yao Yue Gao Mingwu Shen Xiangyang Shi Source Type: research

Integrating machine learning and single-cell trajectories to analyze T-cell exhaustion to predict prognosis and immunotherapy in colon cancer patients
ConclusionIn this study, we systematically explored the T-cell exhaustion trajectory in COAD and developed a TES model to assess prognosis and provide guidelines for the treatment decision. This discovery gave rise to a fresh concept for novel therapeutic procedures for the clinical treatment of COAD.
Source: Frontiers in Immunology - May 3, 2023 Category: Allergy & Immunology Source Type: research

Comprehensive Analysis of NABP2 as a Prognostic Biomarker and Its Correlation with Immune Infiltration in Hepatocellular Carcinoma
CONCLUSION: Based on these findings, NABP2 appears to be a candidate biomarker for HCC prognosis and immunotherapy.PMID:37113629 | PMC:PMC10128078 | DOI:10.2147/JIR.S403370
Source: Cell Research - April 28, 2023 Category: Cytology Authors: Bowen Li Jinghang Liu Liangzhi Xu Qi Xu Zhaohui Liu Tiande Liu Source Type: research

GSE160638 MYC induces immunotherapy and interferon- γ resistance through downregulation of JAK2
Contributors : Ettai Markovits ; Ran Elkon ; Michal J Besser ; Gal MarkelSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensImmunotherapy revolutionized the treatment of advanced melanoma. As the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of pre-immunotherapy tumor biopsies from melanoma patients that received PD-1 blockade (n=36) or adoptive cell therapy with tumor infiltrating lymphocytes (n=37). We identified two melanoma-intrinsic mutually exclusive gene programs, which are controlled by interferon- γ and MYC, and determi...
Source: GEO: Gene Expression Omnibus - April 24, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

MYC induces immunotherapy and interferon- γ resistance through downregulation of JAK2
Cancer Immunol Res. 2023 Apr 19:CIR-22-0184. doi: 10.1158/2326-6066.CIR-22-0184. Online ahead of print.ABSTRACTImmunotherapy has revolutionized the treatment of advanced melanoma. Because the pathways mediating resistance to immunotherapy are largely unknown, we conducted transcriptome profiling of pre-immunotherapy tumor biopsies from melanoma patients that received PD-1 blockade or adoptive cell therapy with tumor-infiltrating lymphocytes. We identified two melanoma-intrinsic, mutually exclusive gene programs, which were controlled by interferon-γ (IFNγ) and MYC, and the association with immunotherapy outcome. MYC-over...
Source: Cell Research - April 19, 2023 Category: Cytology Authors: Ettai Markovits Ortal Harush Erez N Baruch Eldad D Shulman Assaf Debby Orit Itzhaki Liat Anafi Artem Danilevsky Noam Shomron Guy Ben-Betzalel Nethanel Asher Ronnie Shapira-Frommer Jacob Schachter Iris Barshack Tamar Geiger Ran Elkon Michal J Besser Gal Ma Source Type: research

801 Novel nanoparticles mediate efficient siRNA/mRNA co-delivery to melanoma
Checkpoint immunotherapy has revolutionized treatment for patients with advanced or metastatic melanoma; however, many patients ’ tumors either fail to respond or develop secondary resistance. As a result, there is an urgent need for an off-the-shelf local treatment that can improve therapeutic outcomes by increasing immune activation and reducing immunosuppressive factors. We developed a library of novel lipophilic poly(b eta-amino ester) (PBAE)-based biodegradable nanoparticle (NP) formulations with different backbone, sidechain, and endcap monomers and various lipophilic/linear ratios to efficiently co-deliver mRNA an...
Source: Journal of Investigative Dermatology - April 17, 2023 Category: Dermatology Authors: K.M. Luly, E.E. Rocher, J.J. Green, S.Y. Tzeng, J.C. Sunshine Source Type: research

IDO2-siRNA carried by Salmonella combined with nifuroxazide attenuates melanoma growth
CONCLUSION: In conclusion, IDO2-siRNA combined with nifuroxazide therapy could serve a significant role in the treatment of melanoma-bearing mice, enhance the tumor immunity and provide an experimental basis for identifying a novel combination method for the treatment of melanoma clinically.PMID:36999419 | DOI:10.2174/1874467217666230329102030
Source: Cancer Control - March 31, 2023 Category: Cancer & Oncology Authors: Tiesuo Zhao Mengmeng Guo Haoqi Chen Lin Zhou Jing Guo Shenzhen Liu Zizhong Wang Wenshuai Huang Qiang Zhang Jiateng Zhong Mingyong Wang Huijie Jia Yongxi Zhang Source Type: research

Cationic lipid-assisted nanoparticles for simultaneous delivery of CD47 siRNA and R848 to promote antitumor immune responses
Discussion: To our best knowledge, our study pioneered co-delivery system for hydrophilic siCD47 and hydrophobic R848. It can maximize break tumor immune escape caused by CD47 and simultaneously enhance antigen presentation by activating DCs for effector T cell killing while regulating the tumor microenvironment as expected. Not only does it conform to the reports of previous basic research, but also it can break the bottleneck of their clinical application hopefully. Collectively, our findings could lay the foundation for future therapeutic strategies of TNBC.
Source: Frontiers in Pharmacology - March 31, 2023 Category: Drugs & Pharmacology Source Type: research

Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment
Biomed Pharmacother. 2023 Mar 22;161:114567. doi: 10.1016/j.biopha.2023.114567. Online ahead of print.ABSTRACTImmune checkpoint blockade (ICB) therapy targeting the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) axis has achieved considerable success in treating a wide range of cancers. However, most patients with pancreatic cancer remain resistant to ICB. Moreover, there is a lack of optimal biomarkers for the prediction of response to this therapy. Palmitoylation is mediated by a family of 23 S-acyltransferases, termed zinc finger Asp-His-His-Cys-type palmitoyltransferases (ZDHHC), which precisely control vari...
Source: Cancer Control - March 24, 2023 Category: Cancer & Oncology Authors: Zhiqing Lin Keke Huang Hui Guo Manli Jia Qiuqin Sun Xuhao Chen Jianmin Wu Qingqing Yao Peng Zhang Sergii Vakal Zhengzhi Zou Haiyao Gao Lei Ci Jiangfan Chen Wei Guo Source Type: research

Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune response of lung cancer patients. Tumor microenvironment (TME) is an integral tumor microenvironment, which is involved in immunotherapy resistance. Nanomedicine has been used to enhance the immunotherapy in lung cancer. In this review article, we described the association between TME and immunotherapy in lung cancer. We also highligh...
Source: Frontiers in Pharmacology - March 24, 2023 Category: Drugs & Pharmacology Source Type: research

Sialic acid-targeted cyclodextrin-based nanoparticles deliver CSF-1R siRNA and reprogram tumour-associated macrophages for immunotherapy of prostate cancer
Eur J Pharm Sci. 2023 Mar 21;185:106427. doi: 10.1016/j.ejps.2023.106427. Online ahead of print.ABSTRACTProstate cancer remains a serious condition threatening the health of men. Due to the complicated nature of the tumour microenvironment (TME), conventional treatments face challenges including poor prognosis and tumour resistance, therefore new therapeutic strategies are urgently needed. Small interfering RNA (siRNA), a double-stranded non-coding RNA, regulates specific gene expression through RNA interference. Tumour-associated macrophages (TAMs) are a potential therapeutic target in cancer immunotherapy. Colony stimula...
Source: European Journal of Pharmaceutical Sciences - March 22, 2023 Category: Drugs & Pharmacology Authors: Yao Sun Michael F Cronin Monique C P Mendon ça Jianfeng Guo Caitriona M O'Driscoll Source Type: research

Sialic Acid-Targeted Cyclodextrin-Based Nanoparticles Deliver CSF-1R siRNA and Reprogram Tumour-Associated Macrophages for Immunotherapy of Prostate Cancer
Eur J Pharm Sci. 2023 Mar 20:106427. doi: 10.1016/j.ejps.2023.106427. Online ahead of print.ABSTRACTProstate cancer remains a serious condition threatening the health of men. Due to the complicated nature of the tumour microenvironment (TME), conventional treatments face challenges including poor prognosis and tumour resistance, therefore new therapeutic strategies are urgently needed. Small interfering RNA (siRNA), a double-stranded non-coding RNA, regulates specific gene expression through RNA interference. Tumour-associated macrophages (TAMs) are a potential therapeutic target in cancer immunotherapy. Colony stimulating...
Source: European Journal of Pharmaceutical Sciences - March 22, 2023 Category: Drugs & Pharmacology Authors: Yao Sun Michael F Cronin Monique C P Mendon ça Jianfeng Guo Caitriona M O'Driscoll Source Type: research